Homepage
Author:
NEUROCRINE BIOSCIENCES, INC.
Posted Date:
May 7, 2026
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
NEUROCRINE BIOSCIENCES, INC.
May 7, 2026
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
NEUROCRINE BIOSCIENCES, INC.
May 6, 2026
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
NEUROCRINE BIOSCIENCES, INC.
May 5, 2026
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
NEUROCRINE BIOSCIENCES, INC.
May 4, 2026
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-‘2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
NEUROCRINE BIOSCIENCES, INC.
May 4, 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
NEUROCRINE BIOSCIENCES, INC.
May 1, 2026
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
NEUROCRINE BIOSCIENCES, INC.
April 29, 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
NEUROCRINE BIOSCIENCES, INC.
April 22, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
NEUROCRINE BIOSCIENCES, INC.
April 14, 2026
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
NEUROCRINE BIOSCIENCES, INC.
April 14, 2026
1
2
Next
